ApiJect systemsa medical technology company that develops pharmaceutical injection devices, announced the launch of the ApiJect Technology Development Center in the Orlando area.
The new facility will be dedicated to working with pharmaceutical companies to design, engineer and test how to fill and finish their injectable drugs in a new type of single-dose prefilled injector manufactured using the ApiJect platform.
“The ApiJect center is where the future of injection technology will be created. The center adds essential development capability that supports ApiJect’s existing fill-finish lines at our manufacturing partner site in South Carolina, which currently has the capacity to produce up to 540 million single-dose prefilled injectors per year,” said ApiJect’s CEO. Jay Walker said Wednesday.
“Together, these facilities expand the national pharmaceutical supply chain and catalyze our ability here in the United States to be able to address key public health issues such as syringe shortages, syringe safety, and the critical need for state-of-the-art fill-finish capability – not only for this global pandemic, but also for future pandemics and bio-emergencies.
The initial design and construction phase of the center was completed in nine months and on budget. Once fully constructed, the ApiJect Center will contain infrastructure for prototyping and development of devices that meet Food and Drug Administration requirements. Current Good Manufacturing Practices Regulations.
Walker added, “There has been a lot of talk in recent years – rightly so, in my view – about the need to shorten supply chains and have critical technology here in the United States. Our partners in the US government have strongly emphasized this priority since the start of the pandemic. start.
“The ApiJect center was created for this purpose. Its current footprint of 16,000 square feet is just the beginning. Over the next year, the ApiJect center should double in size. As we expand, the current BFS machines will be supplemented by two additional machines. The ApiJect center here in Central Florida will be ground zero for the future of injectable device technology.
The Center is made possible in part by funding of $9.6 million from the HHS Office of the Assistant Secretary for Preparedness and Response. The ASPR leads the federal government’s health care and public health preparedness, response and recovery efforts.
“Strengthening our country’s healthcare supply chain and expanding domestic manufacturing capacity are key priorities for ASPR,” the assistant secretary for preparedness and response said. Dawn O’Connell. “We are pleased to support ApiJect’s efforts to develop new and innovative approaches to how vaccines and injectable medications are filled, finished and delivered so that the nation is prepared for future pandemics and health emergencies.
Bob WardChairman and CEO of the Florida Council of 100 – a leading nonprofit organization comprised of the state’s top 140 presidents and CEOs who provide recommendations on how to further develop the state’s economy – said the expansion of ApiJect supports the Council’s noble goals.
“We are thrilled to welcome ApiJect as another great example of a medical technology company growing Florida’s healthcare innovation sector. ApiJect is exactly the kind of company that is building a strong economic future for our state and its citizens,” he said.
The first potential device realized on the ApiJect platform is the Pre-filled ApiJect injector, an injector designed to efficiently deliver a 0.5 milliliter dose to a patient by simply squeezing a BFS container by a healthcare professional. BFS is the abbreviation of “Blow-Fill-Sealand describes the process of filling a container in a sterile environment without human intervention. The pre-filled ApiJect injector will also allow removable components such as needle hubs.